Altered target gene regulation controlled by estrogen receptor-α concentration

Abstract

Estrogen receptor-α (ERα) is a transcriptional activator whose concentration is tightly regulated by the cellular environment. In breast tumors of post-menopausal women, elevated receptor concentrations can be associated with negative clinical outcomes, yet it remains poorly understood how such high levels impact ERα function. We previously demonstrated that high nuclear concentrations of ERα in breast cancer cells bypass the requirement for ligand and are sufficient to activate transcription and accelerate proliferation. Here, we extended those studies and asked whether the transcriptional targets and activation mechanism are similar or different from that of estrogen-stimulated ERα. We found that at elevated levels, ERα activated, but could not repress, known estrogen-responsive genes. Moreover, the set of activated genes was expanded to include the uterine-restricted target gene, complement component 3. The activation mechanism of ERα under these conditions depends both on activation function-1 and residues in the proximal region of the ligand-binding domain. Mutations of aspartate 351 and leucine 372 can inhibit ERα transcriptional activity gained at high concentrations and discriminate concentration-inducible ERα function from that induced by estrogen. Moreover, we demonstrate that at high levels, ERα stimulates transcription without recruiting steroid receptor coactivator-3 and without interference by a Gal4-receptor interaction domain box fusion protein containing LxxLL motifs, further distinguishing this mode of regulation from known activation mechanisms. Together these results demonstrate that the concentration of receptor in breast cancer cells can influence the pattern of target gene expression through a noncanonical activation mechanism. Copyright © 2006 by The Endocrine Society.